OliX Pharmaceuticals,Inc
KOSDAQTotal Valuation
OliX Pharmaceuticals,Inc carries a market capitalization of 2.74T, placing it among publicly traded companies globally. Its enterprise value stands at 3.74T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.74T |
| Enterprise Value | 3.74T |
Valuation Ratios
The price-to-sales ratio is 221.58, and the price-to-book ratio stands at -20.00.
| PE Ratio | N/A |
| PS Ratio | 221.58 |
| PB Ratio | -20.00 |
| P/TBV Ratio | 26.85 |
| P/FCF Ratio | -198.47 |
| P/OCF Ratio | -182.67 |
Enterprise Valuation
| EV / Sales | 216.66 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
OliX Pharmaceuticals,Inc maintains a current ratio of 6.59, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.99, indicating elevated leverage, while an interest coverage ratio of -26.76 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.59 |
| Quick Ratio | 5.41 |
| Debt / Equity | 14.99 |
| Debt / EBITDA | -0.67 |
| Interest Coverage | -26.76 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -9.59 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 9.51 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, OliX Pharmaceuticals,Inc has paid 2.49B in income taxes, reflecting an effective tax rate of 0.82.
| Income Tax | 2.49B |
| Effective Tax Rate | 0.82 |
Stock Price Statistics
OliX Pharmaceuticals,Inc's stock has gained approximately 247.49035% over the past 52 weeks. The 50-day moving average sits at 155,088.00, while the 200-day moving average is 141,527.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | 247.49035% |
| 50-Day Moving Average | 155,088.00 |
| 200-Day Moving Average | 141,527.50 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, OliX Pharmaceuticals,Inc generated 17.26B in revenue and converted that into -12.25B in net income, yielding earnings per share of -592.68. EBITDA reached -32.52B, while operating income came in at -32.52B.
| Revenue | 17.26B |
| Gross Profit | 17.26B |
| Operating Income | -32.52B |
| Pretax Income | -9.76B |
| Net Income | -12.25B |
| EBITDA | -32.52B |
| EBIT | -32.52B |
| Earnings Per Share (EPS) | -592.68 |
Balance Sheet
OliX Pharmaceuticals,Inc holds 108.39B in cash and equivalents against 21.79B in total debt, resulting in a net debt position of 9.48B. Total book value stands at -191.23B, with working capital of 112.13B providing operational flexibility.
| Cash & Cash Equivalents | 108.39B |
| Total Debt | 21.79B |
| Net Debt | 9.48B |
| Equity (Book Value) | -191.23B |
| Book Value Per Share | -9,253.78 |
| Working Capital | 112.13B |
Cash Flow
OliX Pharmaceuticals,Inc produced -20.94B in operating cash flow over the past twelve months. After subtracting -1.67B in capital expenditures, free cash flow totaled -22.61B - equivalent to -1,093.98 per share.
| Operating Cash Flow | -20.94B |
| Capital Expenditures | -1.67B |
| Free Cash Flow | -22.61B |
| FCF Per Share | -1,093.98 |
Margins
OliX Pharmaceuticals,Inc operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -188.36 and net profit margin of -70.95 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -188.36 |
| Pretax Margin | -56.52 |
| Profit Margin | -70.95 |
| EBITDA Margin | -188.36 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3.17 |
| FCF Yield | -0.50 |
Stock Splits
OliX Pharmaceuticals,Inc's most recent stock split took place on December 3, 2020 with a 1:2 split ratio.
| Last Split Date | 12/3/2020 |
| Split Ratio | 1:2 |
Scores
OliX Pharmaceuticals,Inc posts an Altman Z-Score of 54.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 54.74 |